首页> 外文期刊>Journal of Cancer >Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy
【24h】

Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy

机译:分子靶向药物和生物标志物在非小细胞肺癌中的作用,个体化治疗的发展

获取原文
           

摘要

Lung cancer first line treatment has been directed from the non-specific cytotoxic doublet chemotherapy to the molecular targeted. The major limitation of the targeted therapies still remains the small number of patients positive to gene mutations. Furthermore, the differentiation between second line and maintenance therapy has not been fully clarified and differs in the clinical practice between cancer centers. The authors present a segregation between maintenance treatment and second line and present a possible definition for the term “maintenance” treatment. In addition, cancer cell evolution induces mutations and therefore either targeted therapies or non-specific chemotherapy drugs in many patients become ineffective. In the present work pathways such as epidermal growth factor, anaplastic lymphoma kinase, met proto-oncogene and PI3K are extensively presented and correlated with current chemotherapy treatment. Future, perspectives for targeted treatment are presented based on the current publications and ongoing clinical trials.
机译:肺癌的一线治疗已从非特异性细胞毒双线化疗转向靶向分子。靶向疗法的主要局限性仍然是少数对基因突变呈阳性的患者。此外,二线治疗与维持治疗之间的区别尚未完全阐明,癌症中心之间的临床实践也有所不同。作者提出了维持治疗和第二线之间的隔离,并提出了“维持”治疗一词的可能定义。另外,癌细胞的进化诱导突变,因此在许多患者中靶向治疗或非特异性化疗药物均无效。在目前的工作途径中,诸如表皮生长因子,间变性淋巴瘤激酶,met原癌基因和PI3K等途径被广泛提出,并与当前的化学疗法相关。未来,基于当前的出版物和正在进行的临床试验,提出了靶向治疗的观点。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号